ATE279175T1 - Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens - Google Patents

Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens

Info

Publication number
ATE279175T1
ATE279175T1 AT00957590T AT00957590T ATE279175T1 AT E279175 T1 ATE279175 T1 AT E279175T1 AT 00957590 T AT00957590 T AT 00957590T AT 00957590 T AT00957590 T AT 00957590T AT E279175 T1 ATE279175 T1 AT E279175T1
Authority
AT
Austria
Prior art keywords
skin
methods
fat
cellulite
appearance
Prior art date
Application number
AT00957590T
Other languages
English (en)
Inventor
Howard Murad
Original Assignee
Howard Murad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Murad filed Critical Howard Murad
Application granted granted Critical
Publication of ATE279175T1 publication Critical patent/ATE279175T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00957590T 1999-08-20 2000-08-18 Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens ATE279175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15003499P 1999-08-20 1999-08-20
PCT/US2000/022790 WO2001013865A1 (en) 1999-08-20 2000-08-18 Pharmaceutical compositions and methods for reducing the appearance of cellulite

Publications (1)

Publication Number Publication Date
ATE279175T1 true ATE279175T1 (de) 2004-10-15

Family

ID=22532833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957590T ATE279175T1 (de) 1999-08-20 2000-08-18 Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens

Country Status (7)

Country Link
US (2) US6358539B1 (de)
EP (1) EP1207840B1 (de)
JP (1) JP2003507400A (de)
AT (1) ATE279175T1 (de)
AU (1) AU6918700A (de)
DE (1) DE60014931D1 (de)
WO (1) WO2001013865A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE32570T1 (de) * 1981-12-10 1988-03-15 Revlon Verfahren zur herstellung metallischer blattformender pigmente.
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
JP4182183B2 (ja) * 1999-08-24 2008-11-19 ディーエスエム アイピー アセッツ ビー．ブイ． 痩身用皮膚化粧料
US6808707B2 (en) * 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
US6906045B2 (en) * 2001-03-09 2005-06-14 Wyeth Method for reducing malodor of chondroitin
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US7901873B2 (en) * 2001-04-23 2011-03-08 Tcp Innovations Limited Methods for the diagnosis and treatment of bone disorders
DE10128910A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
DE10128911A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Ascorbinsäure zur Herstellung angiogenetisch wirksamer topischer Zubereitungen
DE10128818A1 (de) * 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Ascorbinsäure und einem oder mehreren Biochinonen zur Herstellung angiogenetisch wirksamer topischer Zubereitungen
WO2003002125A2 (en) * 2001-06-29 2003-01-09 Astion A/S Combination of aminosugars and cysteine or cysteine derivatives
US20030105034A1 (en) * 2001-07-05 2003-06-05 Astion Deveopment A/S Pyridine carboxy derivatives and an aminosugar
AU2002335683B2 (en) * 2001-08-31 2008-11-20 Orthopeutics L.P. Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
US7435722B2 (en) * 2001-08-31 2008-10-14 University Of Southern California Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
US6594739B1 (en) * 2001-09-11 2003-07-15 Emc Corporation Memory system and method of using same
PL370889A1 (en) * 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
CA2503489C (en) * 2002-10-25 2013-09-10 Essentia Biosystems, Inc. Modulation of zinc levels to improve tissue properties
EP1578421A4 (de) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc Pharmazeutische präparate für diebehandlung von erkrankungen und pathologischen zuständen der brust
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CN1816287A (zh) * 2003-01-31 2006-08-09 宝洁公司 改善哺乳动物角质组织外观的方法
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
US7452527B2 (en) * 2003-03-28 2008-11-18 Murad, Inc. Methods of promoting hair growth
US20050043274A1 (en) * 2003-08-22 2005-02-24 Howard Murad Pharmaceutical compositions and methods for lowering blood pressure and pulse rate
JPWO2005027898A1 (ja) * 2003-09-19 2007-11-15 独立行政法人理化学研究所 アミノ酸組成物
EP1730522A2 (de) * 2004-03-29 2006-12-13 Howard Murad Verfahren zur behandlung von dermatologischen erkrankungen
EP1749532B1 (de) * 2004-05-21 2014-04-23 Tottori University Arzneimittel zur heilung oder behanldung von wunden
BRPI0402260B1 (pt) * 2004-06-15 2015-02-18 Botica Com Farmaceutica Ltda Composição para produtos de higiene, cosméticos e perfumes.
US20050282772A1 (en) * 2004-06-21 2005-12-22 Gokaraju Ganga R New dietary supplement composition for obesity and inflammation
US20060130675A1 (en) * 2004-11-30 2006-06-22 Crawford David S Transdermal nutritional supplement delivery patch
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
CA2546464A1 (en) * 2005-05-04 2006-11-04 Richard Wachsberg Sequential application of oral and topical formulations for treating wrinkles and other damage to skin
US20070025950A1 (en) * 2005-07-28 2007-02-01 Elson Melvin L Composition and method for treating cellulite
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US7700083B2 (en) * 2005-10-24 2010-04-20 Kevin Meehan Skin care composition for accelerated production of collagen proteins and method of fabricating same
US20090069638A1 (en) * 2005-12-02 2009-03-12 Howard Murad Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
WO2007120606A2 (en) * 2006-04-10 2007-10-25 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
WO2008047061A2 (fr) * 2006-10-20 2008-04-24 Laboratoires Inneov Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante
FR2907335B1 (fr) * 2006-10-20 2009-08-21 Inneov Lab Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine.
US20080127296A1 (en) * 2006-11-29 2008-05-29 International Business Machines Corporation Identity assurance method and system
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20090269425A1 (en) * 2008-04-28 2009-10-29 Truscott Kent J Formulation and method for relieving or preventing symptoms associated with uric acid crystals
EP2331525A4 (de) 2008-08-11 2013-01-02 Harvard College Halofuginonanaloga zur inhibierung von trna-synthetasen und anwendungen davon
PT104241B (pt) * 2008-10-29 2012-03-06 Stargate Produtos Farmaceuticos Dieteticos E Nutricionais Lda Composições incorporando agentes redutores da celulite e inestetismos associados e formulações que as contêm
US20100261662A1 (en) * 2009-04-09 2010-10-14 Endologix, Inc. Utilization of mural thrombus for local drug delivery into vascular tissue
WO2010124269A1 (en) * 2009-04-24 2010-10-28 National Center For Genome Resources Methods for diagnosis of sepsis and risk of death
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2485687A1 (de) * 2009-10-09 2012-08-15 Vatrix Medical, Inc. Chemische in-vivo-stabilisierung empfindlicher plaque
WO2011116220A2 (en) * 2010-03-17 2011-09-22 Arbonne International Llc Oral supplement
JP2012117827A (ja) * 2010-11-29 2012-06-21 Shiseido Co Ltd オキシタラン線維を指標とした肌理評価法
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
EP2709711B8 (de) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Beschichtete ballons zur blutgefässstabilisierung
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
EP2802572B1 (de) 2012-01-13 2018-11-07 President and Fellows of Harvard College Halofuginol-derivate und ihre verwendung in kosmetischen und pharmazeutischen zusammensetzungen
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
JP7050669B2 (ja) * 2015-10-28 2022-04-08 インデナ エッセ ピ ア 組成物および食品保存におけるその使用
IT201600075108A1 (it) * 2016-07-18 2018-01-18 Italfarmacia S R L 00155 Roma / It Composizione e metodo cosmetico per ridurre gli inestetismi della cellulite.
BR112019018277A2 (pt) 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
JP2019081726A (ja) * 2017-10-30 2019-05-30 日光ケミカルズ株式会社 エラスターゼ活性阻害剤
CA3089831A1 (en) 2018-01-29 2019-08-01 Atolla Skin Health, Inc. Systems and methods for formulating personalized skincare products
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB896940A (en) 1959-02-26 1962-05-23 Pfizer & Co C Healing agent for wounds of the body surface
US3232836A (en) 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
DE1792346C3 (de) 1968-08-22 1980-10-23 Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen
US3773930A (en) 1971-03-23 1973-11-20 Johnson & Johnson Amino acid composition
US4285964A (en) 1979-08-30 1981-08-25 Continental Pharma Salts of (+)-catechine, their preparation and use, and compositions containing these salts
US4414202A (en) 1980-02-19 1983-11-08 Silvetti Anthony N Composition for treatment of wounds
US4486416A (en) 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
IT1148050B (it) 1981-04-30 1986-11-26 Rotta Research Lab Composto stabile della glucosamina solfato procedimento per la sua preparazione e composizioni farmaceutiche contenenti tale composto
EP0066283B1 (de) 1981-06-02 1986-09-10 Eupan Corporation Eustatische Zusammensetzung zur nichtspezifischen Ermöglichung und Verstärkung der gesamten homeostatischen Regulierung und Instandhaltung, Kompensierung und Ausbesserung in lebenden Organismen
US4424232A (en) 1982-05-19 1984-01-03 Parkinson Richard W Treatment of herpes simplex
US4518614A (en) 1982-11-04 1985-05-21 Redken Laboratories, Inc. Cosmetic preparation
US4716224A (en) 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4863907A (en) 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
US4647453A (en) 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
FR2619313B1 (fr) * 1987-08-14 1989-12-29 Claude Christophe Nouvelles compositions d'elements mineraux et/ou oligoelements et leur procede de preparation
FR2623396B1 (fr) 1987-11-25 1990-03-30 Sanofi Sa Utilisation de l'ademetionine contre le vieillissement de la peau
US4938969A (en) 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
IL91928A (en) 1989-10-08 1994-07-31 Amrad Res & Dev Pharmaceutical compositions containing prolactin
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
JPH0429915A (ja) 1990-05-24 1992-01-31 Sunstar Inc 光破砕性リポソーム含有皮膚化粧料
US5308627A (en) 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
GB9207535D0 (en) 1991-04-18 1992-05-20 Ici Plc Compound,composition and use
US5198465A (en) 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
US5296500A (en) 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
US5281196A (en) 1992-05-22 1994-01-25 Sultenfuss Thomas J Skin treatment composition and method of use
US5364845C1 (en) 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
US5415875A (en) 1993-10-22 1995-05-16 Shiseido Co., Ltd. Anti-peroxide external preparation for skin
US5529769A (en) * 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
US5730988A (en) * 1995-04-20 1998-03-24 Lynntech, Inc. Nutritional supplements for improving glucose metabolism
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US6156347A (en) * 1998-01-21 2000-12-05 Bio-Dar Ltd. Controlled release chromium picolinate
AU2904899A (en) 1998-03-16 1999-10-11 Procter & Gamble Company, The Compositions for regulating skin appearance
KR20010041902A (ko) 1998-03-16 2001-05-25 데이비드 엠 모이어 포유류의 피부 내의 셀룰라이트를 감소시키는 방법

Also Published As

Publication number Publication date
EP1207840A1 (de) 2002-05-29
EP1207840B1 (de) 2004-10-13
US20020137691A1 (en) 2002-09-26
US6358539B1 (en) 2002-03-19
JP2003507400A (ja) 2003-02-25
WO2001013865A1 (en) 2001-03-01
US6676977B2 (en) 2004-01-13
DE60014931D1 (de) 2004-11-18
EP1207840A4 (de) 2002-10-30
AU6918700A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ATE279175T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens
US5198465A (en) Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
MX2007006707A (es) Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
WO2008033464A3 (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
EP2305276A3 (de) Zellen aus Lipoaspirat und ihre Verwendung zur Therapie
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
EP1677806A4 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
US20040086581A1 (en) Bio-energetic joint and arthritis pain formula
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
WO2003024486A1 (en) Remedies for bone loss
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
ATE466587T1 (de) Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe
MD885G2 (ro) Metodă de tratament al colitei, hepatitei, pielonefritei, maladiilor alergice ale tegumentelor şi căilor respiratorii
UA37540A (uk) Спосіб лікування діабетичних ангіопатій у хворих на туберкульоз

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties